Precedex is a brand name of dexmedetomidine, approved by the FDA in the following formulation(s):
PRECEDEX (dexmedetomidine hydrochloride - injectable; injection)
Manufacturer: HOSPIRA
Approval date: December 17, 1999
Strength(s): EQ 100MCG BASE/ML (EQ100MCG BASE/ML) [RLD]
Has a generic version of Precedex been approved?
No. There is currently no therapeutically equivalent version of Precedex available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Precedex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist
Patent 4,910,214
Issued: March 20, 1990
Inventor(s): Karjalainen; Arto J. & Virtanen; Raimo E. & Savolainen; Eino J.
Assignee(s): Farmos Yhtyma Oy
The separated d and l enantiomers of medetomidine and their salts are selective and potent .alpha..sub.2 -receptor agonists.
Patent expiration dates:
4-substituted imidazole derivatives useful in perioperative care
Patent 5,344,840
Issued: September 6, 1994
Inventor(s): Maze; Mervyn & Scheinin; Mika
Assignee(s): Orion-Yhtyma OY
4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, known as medetomidine, and in particular its d-enantiomer and salts thereof are useful in perioperative care, in particular in reducing the amount of anaesthetic it is necessary to administer.
Patent expiration dates:
Use of dexmedetomidine for ICU sedation
Patent 6,716,867
Issued: April 6, 2004
Inventor(s): Riku; Aantaa & Romeo; Bachand & Esa; Heinonen
Assignee(s): Orion Corporation
The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
Patent expiration dates:
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
See also...
- Precedex AHFS DI Monographs (ASHP)
- Dexmedetomidine Hydrochloride AHFS DI Monographs (ASHP)